TransCode Therapeutics Advances RNA Cancer Therapy, Treats 15 Patients in Phase 1a Trial

TransCode Therapeutics has reported significant progress in its Phase 1a clinical trial for TTX-MC138, an innovative RNA-based cancer therapeutic targeting metastatic tumors. The company has successfully dosed 15 patients across four different dose levels, with the Safety Review Committee approving expanded enrollment based on preliminary findings.

The trial's early results are encouraging. Ten patients remain under active study, with the longest-treated patient showing stable disease after seven treatment cycles. Pharmacokinetic and pharmacodynamic data have confirmed target engagement, suggesting the potential effectiveness of the experimental therapy.

The TTX-MC138 therapy specifically targets tumors overexpressing microRNA-10b, a biomarker associated with metastasis. This approach represents a novel strategy in cancer treatment, focusing on addressing the challenging aspect of cancer spread.

These initial findings are particularly significant in the oncology field, where metastatic cancer remains one of the most difficult conditions to treat. The absence of reported significant toxicities and the observation of stable disease suggest that this RNA therapeutic approach could offer a promising alternative for patients with challenging cancer diagnoses.

The successful completion of this phase sets the stage for TransCode Therapeutics to advance to the Phase 1b dose expansion stage, potentially bringing this innovative treatment closer to broader clinical application.